Drug Type TCR therapy |
Synonyms- |
Target |
Mechanism NY-ESO-1 inhibitors(Cancer/testis antigen 1 inhibitors), T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | Phase 2 | IL | 01 Apr 2022 | |
Neuroblastoma | Phase 2 | IL | 01 Apr 2022 | |
Non-Small Cell Lung Cancer | Phase 2 | IL | 01 Apr 2022 | |
Ovarian Cancer | Phase 2 | IL | 01 Apr 2022 | |
Synovial Sarcoma | Phase 2 | IL | 01 Apr 2022 | |
Triple Negative Breast Cancer | Phase 2 | IL | 01 Apr 2022 | |
Urothelial Carcinoma of the Urinary Bladder | Phase 2 | IL | 01 Apr 2022 |